Pfizer Inc. said it has reached a pricing agreement with the Trump Administration aimed at reducing prescription drug costs for U.S. patients while bolstering domestic pharmaceutical investment.  Under the voluntary deal, Pfizer will align prices of newly launched medicines with those in other developed countries and offer significant discounts—averaging 50% and up to 85%—on a broad range of primary care and select specialty treatments through a new direct purchasing platform, TrumpRx.go...